# Immunocore Holdings plc (IMCR) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/IMCR
## Company Profile
- Ticker: IMCR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United Kingdom
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 34.18 USD
- Market cap: 1503586367.4399998 USD
- Last updated: 2026-08-11
## Business Overview
### ImmTAX TCR Platform
Immunocore is a commercial-stage biotechnology company developing off-the-shelf bispecific T-cell receptor therapies. Its ImmTAX platform is designed to redirect immune cells against disease-associated targets across oncology, infectious disease and autoimmune disease.
### KIMMTRAK Franchise
KIMMTRAK, or tebentafusp, is approved in dozens of countries for HLA-A*02:01-positive unresectable or metastatic uveal melanoma. The therapy is the company’s commercial foundation and the first approved product from its TCR bispecific platform.
### Tebentafusp Expansion Programs
Immunocore is testing tebentafusp in the registrational TEBE-AM Phase 3 trial for previously treated advanced cutaneous melanoma. A separate Phase 3 study, ATOM, is evaluating the therapy in high-risk adjuvant uveal melanoma.
### PRAME Oncology Portfolio
Brenetafusp is the lead PRAME-targeted ImmTAC and is in the Phase 3 PRISM-MEL-301 trial for first-line advanced cutaneous melanoma, alongside Phase 1/2 work in ovarian and lung cancers. IMC-P115C is a half-life-extended PRAME candidate in Phase 1 development, while IMC-R117C targets PIWIL1 in colorectal and other gastrointestinal cancers.
### Infectious Disease Programs
The ImmTAV platform applies TCR bispecifics to virally infected cells. IMC-M113V is in Phase 1/2 development for HIV and is intended to support sustained viral control after patients discontinue antiretroviral therapy.
### Autoimmune Expansion
Immunocore’s ImmTAAI molecules are designed to suppress pathogenic T cells selectively within targeted tissue. The initial portfolio includes IMC-S118AI for type 1 diabetes and IMC-U120AI for inflammatory dermatologic disease.
## Why The Stock Is Moving

As of Aug 11, 2026, IMCR closed up 0.59% at $34.18. No new same-company headline was identified in the current news window.

## Future Catalysts

- Completion of enrollment in the TEBE-AM Phase 3 trial expected in the first half of 2026, with topline data possible in the second half of 2026.
- Phase 1/2 data for brenetafusp and IMC-P115C expected in the second half of 2026.
- Additional Phase 1 multiple-ascending-dose data for IMC-M113V expected in the second half of 2026.
- Phase 1 initiation for IMC-S118AI planned in the first half of 2026.
- CTA or IND filing for IMC-U120AI planned in the second half of 2026.
- Initial clinical data for IMC-R117C expected in 2027.

## Recent News
- 2026-08-06 11:00 EST — [Immunocore reports second quarter financial results and provides a business update](https://biopharmsignal.com/news/IMCR/immunocore-reports-second-quarter-financial-results-and-provides-a-business-upda-ab8c4319) — Source: Immunocore Holdings plc
- 2026-07-30 11:00 EST — [Immunocore to report second quarter 2026 financial results and host call on August 6, 2026](https://biopharmsignal.com/news/IMCR/immunocore-to-report-second-quarter-2026-financial-results-and-host-call-on-augu-527188fc) — Source: Immunocore Holdings plc
- 2026-05-31 12:00 EST — [Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma](https://biopharmsignal.com/news/IMCR/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma) — Source: Immunocore Holdings plc
- 2026-05-06 11:00 EST — [Immunocore reports first quarter financial results and provides a business update](https://biopharmsignal.com/news/IMCR/immunocore-reports-first-quarter-financial-results-and-provides-a-business-update) — Source: Immunocore Holdings plc
- 2026-04-19 22:00 EST — [KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma](https://biopharmsignal.com/news/IMCR/kimmtrak-doubles-the-likelihood-of-being-alive-at-five-years-for-first-line-hla-a-02-01-patients-with-metastatic-uveal-melanoma) — Source: Immunocore Holdings plc